| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.0005 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0009 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.095 | 0.002 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.094 | 0.003 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.004 |